Summa Equity acquires majority stake in SG-based biotech firm Sengenics

Summa Equity acquires majority stake in SG-based biotech firm Sengenics

Summa Equity Fund II has acquired a majority stake in Singapore proteomics company Sengenics, paving the exit of SBI Islamic Fund II (Brunei).

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter